The prevalence of multidrug-resistant tuberculosis has not only affected India but has also impacted other countries such as Africa. Multi-drug resistant tuberculosis is when regular medicines such as isoniazid and rifampin are one of the two anti-tuberculosis drugs used, resistance can occur either from not following proper treatment guidelines or from a drug-resistant bacterium, tuberculosis can be caused by Mycobacterium Tuberculosis a bacterium that causes tuberculosis that attacks the lungs. Tuberculosis occurs through droplet infection and is extremely contagious, due to the multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) nature. Many drugs are expensive and difficult to find. MDR-TB is caused due to improper adherence to the treatment the person is said to be taking, MDR-TB can also be caused to someone who has had a previous case of tuberculosis. Treatment of MDR-TB is expensive and paucity of funding is debilitating further treatment of tuberculosis and its various forms; tuberculosis could prove fatal if not treated promptly. Patients with MDR-TB had noticed weight loss, the recovery time for patients was longer than the time taken for drug-resistant tuberculosis. The availability of cheaper, less toxic drugs would aid tuberculosis treatment and improve care in hospitals and other institutions. India is one of the countries with the highest number of recorded XDR-TB cases. Early diagnosis of tuberculosis is expensive but it is necessary to save people from dyeing, this problem arises due to lack of funding provided for tuberculosis research and treatment....... middle of paper..... . treatment of drug-susceptible and multidrug-resistant tuberculosis." Journal of Infection and Public Health Available online November 9, 2013 (2013): page no. ScienceDirect. Web. November 24, 2013. "Resources." ACTION.org. Global Health Advocacy Leadership, nd Web. 23 November 2013. "The Five Elements of DOTS WHO, nd Web. 23 November 2013. "Tuberculosis Diagnositics smear microscopy?”. The Hindu, nd Web. 2013. .